Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Metformin (Primary)
- Indications Diastolic heart failure; Left ventricular dysfunction; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms MET-DIME
- 19 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
- 19 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2018.
- 31 Aug 2018 Biomarkers information updated